Cellectis (ALCLS) Q1 2026 earnings summary

Executive summary

• Reported Q1 2026 financial results and provided business updates on clinical and preclinical programs.

• Interim pivotal data for cema-cel (licensed product) showed strong MRD negativity and safety profile.

• Pivotal Phase 2 interim analysis for lasme-cel in r/r B-ALL expected Q4 2026; BLA submission anticipated in 2028.

• Full Phase 1 dataset for eti-cel in NHL expected in Q4 2026.

• Highlighted innovation in TALE-based epigenetic editing and key partnership milestones.

Financial highlights

• Cash, cash equivalents, and fixed-term deposits totaled $188 million as of March 31, 2026, providing runway into Q4 2027.

• Revenues and other income were $7.5 million for Q1 2026, down from $12.0 million in Q1 2025, mainly due to lower activity under the AstraZeneca agreement.

• R&D expenses increased to $27.2 million from $21.9 million year-over-year, driven by higher personnel and external costs.

• SG&A expenses rose to $5.6 million from $4.7 million, mainly due to increased stock-based compensation and other expenses.

• Net financial gain of $7.4 million in Q1 2026, compared to a $3.9 million loss in Q1 2025, due to gains on warrant fair value and FX movements.

• Net loss attributable to shareholders was $17.8 million ($0.18/share), slightly improved from $18.1 million ($0.18/share) in Q1 2025.

• Adjusted net loss was $16.1 million ($0.16/share), compared to $17.2 million ($0.17/share) in Q1 2025.

Outlook and guidance

• Interim pivotal Phase 2 data for lasme-cel and full Phase 1 data for eti-cel anticipated in Q4 2026.

• BLA submission for lasme-cel targeted for 2028.

• Cash runway projected into Q4 2027, supporting ongoing clinical development and manufacturing.